- Home
- Publications
- Publication Search
- Publication Details
Title
Antisense technology: an overview and prospectus
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-25
DOI
10.1038/s41573-021-00162-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells
- (2020) Chiara De Santi et al. MOLECULAR THERAPY
- Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
- (2020) Diane E. Frank et al. NEUROLOGY
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
- (2020) Michael E Østergaard et al. NUCLEIC ACIDS RESEARCH
- Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia
- (2020) PadmaKumar Narayanan et al. Nucleic Acid Therapeutics
- The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy
- (2020) Annemieke Aartsma-Rus et al. Nucleic Acid Therapeutics
- Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
- (2020) Marco Luigetti et al. Therapeutics and Clinical Risk Management
- Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial
- (2020) T. H. Brannagan et al. EUROPEAN JOURNAL OF NEUROLOGY
- Phosphorothioate modified oligonucleotide–protein interactions
- (2020) Stanley T Crooke et al. NUCLEIC ACIDS RESEARCH
- Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
- (2020) Paula R. Clemens et al. JAMA Neurology
- Antisense Drug Discovery and Development Technology Considered in a Pharmacological Context
- (2020) Stanley T. Crooke et al. BIOCHEMICAL PHARMACOLOGY
- Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis
- (2020) Hangying Ying et al. CARDIOVASCULAR DRUGS AND THERAPY
- Viltolarsen: First Approval
- (2020) Sohita Dhillon DRUGS
- The Interaction of Phosphorothioate Containing RNA Targeted Drugs with Proteins is a Critical Determinant of The Therapeutic Effects of These Agents
- (2020) Stanley Crooke et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
- (2020) Timothy Miller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
- (2020) Rohit Loomba et al. Lancet Gastroenterology & Hepatology
- Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
- (2020) Daniel Gaudet et al. EUROPEAN HEART JOURNAL
- Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema
- (2020) Danny M. Cohn et al. NEW ENGLAND JOURNAL OF MEDICINE
- miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma
- (2020) Teresa Fuertes et al. TRENDS IN IMMUNOLOGY
- Dietary Strategies for Metabolic Syndrome: A Comprehensive Review
- (2020) Sara Castro-Barquero et al. Nutrients
- Therapeutic advances of miRNAs: A preclinical and clinical update
- (2020) Chiranjib Chakraborty et al. Journal of Advanced Research
- Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo
- (2020) Eleni Anastasiadou et al. CLINICAL CANCER RESEARCH
- Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
- (2020) Nicholas J. Viney et al. ESC Heart Failure
- IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production
- (2019) Jason D. Ferrone et al. Nucleic Acid Therapeutics
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia – spotlight on volanesorsen
- (2019) Dimitrios Milonas et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy
- (2019) Erin S. Morgan et al. DIABETES CARE
- Therapeutic Antisense Oligonucleotides Are Coming of Age
- (2019) C. Frank Bennett Annual Review of Medicine
- The Chylomicronemia Syndrome Is Most Often Multifactorial
- (2019) Alan Chait et al. ANNALS OF INTERNAL MEDICINE
- N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
- (2019) Veronica J Alexander et al. EUROPEAN HEART JOURNAL
- FRI-106-Combining endozepine-4 and blood ammonia: Does it improve the diagnosis of hepatic encephalopathy in patients with liver cirrhosis?
- (2019) Ayman El Shayeb et al. JOURNAL OF HEPATOLOGY
- Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
- (2019) Wen Shen et al. NATURE BIOTECHNOLOGY
- Targeting Huntingtin Expression in Patients with Huntington’s Disease
- (2019) Sarah J. Tabrizi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins
- (2019) Michael T Migawa et al. NUCLEIC ACIDS RESEARCH
- Current Development of siRNA Bioconjugates: From Research to the Clinic
- (2019) Ivan V. Chernikov et al. Frontiers in Pharmacology
- Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
- (2019) C. Frank Bennett et al. Annual Review of Neuroscience
- SOLAR: A PHASE 2, GLOBAL, RANDOMIZED, ACTIVE COMPARATOR STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBOMARSEN IN SUBJECTS WITH MYCOSIS FUNGOIDES (MF)
- (2019) A.M. James et al. HEMATOLOGICAL ONCOLOGY
- Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis
- (2019) Pavel Drevinek et al. Journal of Cystic Fibrosis
- Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models
- (2019) Youngsoo Kim et al. MOLECULAR THERAPY
- Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
- (2019) Jacqueline Montes et al. MUSCLE & NERVE
- mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
- (2019) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis
- (2019) Wouter Beumer et al. PLoS One
- Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis
- (2019) Morie A. Gertz et al. Expert Review of Clinical Pharmacology
- An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
- (2019) Basil T. Darras et al. CNS DRUGS
- A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
- (2019) Gagan D. Flora et al. CURRENT PHARMACEUTICAL DESIGN
- Targeting the IL-17 receptor using liposomal spherical nucleic acids as topical therapy for psoriasis
- (2019) Haoming Liu et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
- (2019) Darryl C. De Vivo et al. NEUROMUSCULAR DISORDERS
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- (2019) Joseph L. Witztum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
- (2019) Charles A. German et al. BIODRUGS
- O.28Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial
- (2019) K. Wagner et al. NEUROMUSCULAR DISORDERS
- Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1
- (2019) Timothy A Vickers et al. NUCLEIC ACIDS RESEARCH
- Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma
- (2019) Xiangjun Tang et al. Frontiers in Oncology
- Mongersen (GED-0301) for Active Crohnʼs Disease
- (2019) Bruce E. Sands et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomes
- (2019) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- RNA-Targeted Therapeutics
- (2018) Stanley T. Crooke et al. Cell Metabolism
- Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B Rx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes
- (2018) Andres Digenio et al. DIABETES CARE
- Locked nucleic acid: modality, diversity, and drug discovery
- (2018) Peter H. Hagedorn et al. DRUG DISCOVERY TODAY
- A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly
- (2018) Peter J Trainer et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
- (2018) Donald J. Foster et al. MOLECULAR THERAPY
- Eteplirsen treatment for Duchenne muscular dystrophy
- (2018) Jay S. Charleston et al. NEUROLOGY
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
- (2018) Merrill D. Benson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
- (2018) Eugenio Mercuri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides
- (2018) Shiyu Wang et al. NUCLEIC ACIDS RESEARCH
- The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
- (2018) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
- (2018) Aaron D. Springer et al. Nucleic Acid Therapeutics
- Antisense oligonucleotide targeting of mRNAs encoding ENaC subunits α, β, and γ improves cystic fibrosis-like disease in mice
- (2018) Chenguang Zhao et al. Journal of Cystic Fibrosis
- Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
- (2018) Isabelle Sermet-Gaudelus et al. Journal of Cystic Fibrosis
- Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect
- (2018) Artur V. Cideciyan et al. NATURE MEDICINE
- Post-transcriptional control of miRNA biogenesis
- (2018) Gracjan Michlewski et al. RNA
- Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
- (2018) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- Targeted delivery of antisense oligonucleotides to pancreatic β-cells
- (2018) C. Ämmälä et al. Science Advances
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
- (2018) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Entering the Modern Era of Gene Therapy
- (2018) Xavier M. Anguela et al. Annual Review of Medicine
- Alicaforsen in the treatment of pouchitis
- (2017) Thomas Greuter et al. Immunotherapy
- RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions
- (2017) A. Robert MacLeod et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice
- (2017) Jeff R. Crosby et al. Journal of Cystic Fibrosis
- A Test in Context: Lipoprotein(a)
- (2017) Sotirios Tsimikas JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Improving childhood cancer care in Latin America and the Caribbean: a PAHO Childhood Cancer Working Group position statement
- (2017) Avram Denburg et al. LANCET ONCOLOGY
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
- (2017) Mark J. Graham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs
- (2017) Xue-Hai Liang et al. NUCLEIC ACIDS RESEARCH
- Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
- (2017) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
- (2017) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
- (2017) Norbert Pfeiffer et al. PLoS One
- A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
- (2016) K. N. Chi et al. ANNALS OF ONCOLOGY
- Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
- (2016) Andres Digenio et al. DIABETES CARE
- A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)
- (2016) S. Chowdhury et al. EUROPEAN JOURNAL OF CANCER
- Approving a Problematic Muscular Dystrophy Drug
- (2016) Aaron S. Kesselheim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles
- (2016) Tsukasa Sugo et al. JOURNAL OF CONTROLLED RELEASE
- The Medicinal Chemistry of Therapeutic Oligonucleotides
- (2016) W. Brad Wan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
- (2016) Richard S Finkel et al. LANCET
- Modern Management of Familial Hypercholesterolemia
- (2016) P. Barton Duell et al. Metabolic Syndrome and Related Disorders
- Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
- (2016) Stanley T Crooke et al. MOLECULAR THERAPY
- Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames
- (2016) Xue-hai Liang et al. NATURE BIOTECHNOLOGY
- Non-coding RNAs as drug targets
- (2016) Masayuki Matsui et al. NATURE REVIEWS DRUG DISCOVERY
- Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
- (2016) Claudia A. Chiriboga et al. NEUROLOGY
- RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery
- (2016) Walt F. Lima et al. NUCLEIC ACIDS RESEARCH
- Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver
- (2016) Colton M. Miller et al. NUCLEIC ACIDS RESEARCH
- Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
- (2016) Nathalie M. Goemans et al. PLoS One
- Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
- (2015) Richard S. Geary et al. ADVANCED DRUG DELIVERY REVIEWS
- Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma
- (2015) M. H. van der Ree et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
- (2015) Richard S. Geary et al. CLINICAL PHARMACOKINETICS
- Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia
- (2015) Raul D. Santos et al. Journal of Clinical Lipidology
- Antisense oligonucleotide–directed inhibition of nonsense-mediated mRNA decay
- (2015) Tomoki T Nomakuchi et al. NATURE BIOTECHNOLOGY
- Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
- (2015) Harry R. Büller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
- (2015) Giovanni Monteleone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages
- (2015) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
- (2014) Jayaprakash K. Nair et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
- (2014) Thomas Voit et al. LANCET NEUROLOGY
- CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
- (2014) V. Limmroth et al. NEUROLOGY
- Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides
- (2014) Amanda J. Ward et al. NUCLEIC ACIDS RESEARCH
- Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
- (2014) W. Brad Wan et al. NUCLEIC ACIDS RESEARCH
- Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice
- (2014) Thazha P. Prakash et al. NUCLEIC ACIDS RESEARCH
- Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
- (2014) Walt F. Lima et al. PLoS One
- Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms
- (2014) Timothy A. Vickers et al. PLoS One
- Eteplirsen for the treatment of Duchenne muscular dystrophy
- (2013) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells
- (2013) Xue-hai Liang et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- RNA helicase A is not required for RISC activity
- (2013) Xue-hai Liang et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
- (2013) D Bianchini et al. BRITISH JOURNAL OF CANCER
- An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
- (2013) Timothy M Miller et al. LANCET NEUROLOGY
- Treatment of HCV Infection by Targeting MicroRNA
- (2013) Harry L.A. Janssen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics
- (2013) Richard G. Lee et al. Journal of Cardiovascular Translational Research
- Single-Stranded siRNAs Activate RNAi in Animals
- (2012) Walt F. Lima et al. CELL
- Antisense oligonucleotides for the treatment of dyslipidaemia
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
- (2012) Anette Varbo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Unique Gene-Silencing and Structural Properties of 2′-Fluoro-Modified siRNAs
- (2011) Muthiah Manoharan et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy
- (2011) Frederick J. Raal et al. CIRCULATION
- A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer
- (2011) D. S. Hong et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
- (2011) F. Saad et al. CLINICAL CANCER RESEARCH
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
- (2011) Sebahattin Cirak et al. LANCET
- Regulation of mRNA Translation and Stability by microRNAs
- (2010) Marc Robert Fabian et al. Annual Review of Biochemistry
- Genetic determinants of plasma triglycerides
- (2010) Christopher T. Johansen et al. JOURNAL OF LIPID RESEARCH
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Exploring Chemical Modifications for siRNA Therapeutics: A Structural and Functional Outlook
- (2009) Siddharth Shukla et al. ChemMedChem
- Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs
- (2009) Aly A Khan et al. NATURE BIOTECHNOLOGY
- Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 ‘Slicer’ independent and can be mediated by Ago1
- (2009) Timothy A. Vickers et al. NUCLEIC ACIDS RESEARCH
- Comparing In Vitro and In Vivo Activity of 2′-O-[2-(Methylamino)-2-oxoethyl]- and 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
- (2008) Thazha P. Prakash et al. JOURNAL OF MEDICINAL CHEMISTRY
- Oral Delivery of Antisense Oligonucleotides in Man
- (2007) Lloyd G. Tillman et al. JOURNAL OF PHARMACEUTICAL SCIENCES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now